Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
Date:11/9/2009

itional $20.0 million under similar terms, with the additional loan also maturing in June 2013. For each additional $1.0 million in funding, Arena will issue Deerfield additional warrants for 280,000 shares of its common stock at an exercise price of $5.42 per share. Arena repaid Deerfield the first scheduled principal repayment of $10.0 million upon completion of its public offering in July.

Scheduled Earnings Call

Arena will host both a conference call and webcast to discuss the third quarter 2009 financial results and to provide a business and financial update tomorrow, Tuesday, November 10, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Jack Lief, President and Chief Executive Officer, and Robert E. Hoffman, Vice President, Finance and Chief Financial Officer, will host the conference call.

The conference call may be accessed by dialing 888.452.4024 for domestic callers and 719.325.2385 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Third Quarter 2009 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Upcoming Corporate Presentations

Arena is planning to present at upcoming investment and industry conferences, including:

  • Piper Jaffray 21st Annual Health Care Conference, December 1-2, 2009, New York, New York
  • 28th Annual J.P. Morgan Healthcare Conference, January 11-14, 2010, San Francisco, California

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on dis
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014  CVS Caremark Corporation (NYSE: ... on Tuesday, August 5, 2014, at 8:30 a.m. (EDT) ... 2014 financial results. An audio webcast of ... Investor Relations portion of the CVS Caremark website for ... http://info.cvscaremark.com/investors . This webcast will be archived and available ...
(Date:7/25/2014)... N.J. , July 25, 2014  Acsis ... brand protection and serialization solutions, has recently posted ... that addresses current and future needs for ... for the old supply chain model no longer ... in technology, including the growth of mobile technology, ...
(Date:7/25/2014)... , July 25, 2014 Research ... "Global Ophthalmic Diagnostic Devices Market 2014-2018" report ... About Ophthalmic Diagnostic Device ... used to identify a defect or deficiency in the ... with ophthalmic disorders such as presbyopia, cataracts, glaucoma, retinal ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... Filtrona Porous Technologies, a developer and manufacturer of ... world, will introduce a new range of hydrophilic, polyurethane ... / COMPAMED trade fair in Dusseldorf, Germany from 16 ... ) New innovations to be featured ...
... Nordisk, a world leader in diabetes care, announced today that ... (DHF), a non-profit organization that raises diabetes awareness ... the success of the Drive the Switch program, which has ... loved ones and their doctor about options for insulin delivery, ...
Cached Medicine Technology:Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair 2Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 2Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 3Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 4Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 5Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 6Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 7
(Date:7/25/2014)... Ticket Down is a reliable source for cheap ... California Memorial Stadium. With the post-World Cup emotions still rolling ... the 2014 Guinness International Champions Cup have brought eight of ... representing La Liga, English Premier League, Serie A, and Superleague ... players from around the world to 12 American cities and ...
(Date:7/25/2014)... 25, 2014 On July 22, ... Media client and the nation’s number one provider ... handbooks, announced their partnership with TransAct Merchant Solutions’ ... registered ISO/MSP of Chase Paymentech Solutions, LLC, which ... industry. Companies that are members of TransAct’s National ...
(Date:7/25/2014)... July 25, 2014 Hastings and ... discount attorney’s fees with regard to personal injury claims, ... a wide range of legal services for those that ... of another individual or corporation. Free initial consultation services ... validity of a potential personal injury claim . ...
(Date:7/25/2014)... especially men, may be at higher risk for type 2 ... study suggests. Also at special risk are shift workers ... around at various times of the day. The findings ... Manevitz, a clinical psychiatrist at Lenox Hill Hospital in New ... disrupts many key body chemicals, creating a ripple effect that ...
(Date:7/25/2014)... An experimental anti-inflammatory drug can protect vulnerable neurons ... of Parkinson,s disease, researchers at Emory University School ... published in the Journal of Parkinson,s Disease ... called XPro1595, can reach the brain at sufficient ... subcutaneous injection, like an insulin shot. Previous studies ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2
... CA Scientists at the Salk Institute for Biological Studies have ... protein in cells. The protein, p53, can cause cells to ... signs of DNA damage, and it is responsible for much ... or DNA-damaging drugs such as the ones commonly used for ...
... patients with certain other health problems have higher mortality ... study published online June 30 in the Journal ... problems, or ,comorbidities, include heart attack and other heart-related ... Previous studies have shown that comorbidities as a group ...
... Today the International and American Associations for Dental Research announced ... ) has increased its Five-Year Scientific Impact Factor (SIF) from ... category, the Journal ranked #1 in Article Influence. This news ... rankings, published by the Journal Citation Reports (JCR). This latest ...
... researchers from Boston University School of Medicine (BUSM) and ... high rate of thyroid function testing in pregnant women. ... the Journal of Clinical Endocrinology & Metabolism , ... testing on pregnant women, approximately 80 percent of cases ...
... in young adult mice that a lone brain stem cell is ... neurons and glia important types of brain cells but ... stem cells. A report on their study appears June 24 ... brain has the capacity to generate both neurons, which send and ...
... Reinberg HealthDay Reporter , THURSDAY, June 30 (HealthDay ... up in emergency rooms for drinking-related injuries doubles over the ... and 4, drinking sends a daily average of nearly 1,000 ... the ER for problems related to alcohol use, according to ...
Cached Medicine News:Health News:The genome guardian's dimmer switch: Regulating p53 is a matter of life or death 2Health News:The genome guardian's dimmer switch: Regulating p53 is a matter of life or death 3Health News:Worse outcomes for older breast cancer patients with other health problems 2Health News:Journal of Dental Research increases its scientific impact factor 2Health News:BMC conducts high rates of thyroid testing in pregnant women, study finds 2Health News:Nervous system stem cells can replace themselves, give rise to variety of cell types, even amplify 2Health News:July 4 Weekend Dangerous for Underage Boys Who Drink: Report 2
... breakthrough continuous low-flow nebulizer performance. Patented ... technology allows for optimal medication and ... Heliox). OMNI~NEB takes on severe asthma, ... and critical care situations. Configure with ...
... developing diverse medical products for ... medical-surgical products have earned an ... and customer satisfaction. Graham-Fields internationally ... line of diagnostic instruments, Grafco® ...
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
Medicine Products: